13D Filing: JFL Capital Management and Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Page 8 of 12

Page 8 of 12 – SEC Filing

(f)       JFL
Partners, JFL Holdings and JFL Capital Management are organized under the laws of the State of Delaware. JFL GP is organized under
the laws of the State of Texas. Dr. Lawler is a citizen of the United States of America.

Item 3. Source and Amount of Funds or Other Consideration.

The Shares purchased
by JFL Partners and held in the JFL Account were purchased with working capital (which may, at any given time, include margin loans
made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 345,734 Shares beneficially owned
by JFL Partners is approximately $1,363,987, including brokerage commissions. The aggregate purchase price of the 595,768 Shares
held in the JFL Account is approximately $2,350,277, including brokerage commissions.

Item 4. Purpose of Transaction.

The Reporting Persons purchased
the Shares based on the Reporting Persons’ belief that the Shares, when purchased, were undervalued and represented an attractive
investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons,
and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor
to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market
or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable.

The Reporting Persons have
engaged, and intend to continue to engage, in communications with the Issuer’s management team and Board of Directors (the
“Board”) regarding means to enhance stockholder value.

No Reporting Person has any
present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) – (j) of Item 4 of
Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the
actions discussed herein. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending
on various factors including, without limitation, the Issuer’s financial position and investment strategy, the price levels
of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in
the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation,
engaging in additional communications with management and the Board of the Issuer, engaging in discussions with stockholders of
the Issuer and others about the Issuer and the Reporting Persons’ investment, making proposals to the Issuer concerning changes
to the capital allocation strategy, capitalization, ownership structure, Board structure (including Board composition) or operations
of the Issuer, purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or
similar transaction with respect to the Shares, or changing their intention with respect to any and all matters referred to in
Item 4.

Item 5. Interest in Securities of the Issuer.

(a)       The
aggregate percentage of Shares reported owned by each person named herein is based upon 13,342,784 Shares outstanding as of August
2, 2018, which is the total number of Shares outstanding as reported in the Issuer’s quarterly report on Form 10-Q filed
with the Securities and Exchange Commission on August 7, 2018.

8

Follow Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Page 8 of 12